Manufacturer of Controlled Substances Notice of Registration, 47962-47963 [E9-22453]

Download as PDF 47962 Federal Register / Vol. 74, No. 180 / Friday, September 18, 2009 / Notices the basic classes of controlled substances listed. DEPARTMENT OF JUSTICE Drug Enforcement Administration Dated: September 14, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–22505 Filed 9–17–09; 8:45 am] BILLING CODE 4410–09–M DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances Notice of Registration DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances Notice of Registration Manufacturer of Controlled Substances; Notice of Application By Notice dated June 15, 2009, and published in the Federal Register on June 24, 2009, (74 FR 30111), AllTech Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II: Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 2, 2009, GE Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004–1412, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance in schedule II. The company plans to manufacture a radioactive product used in diagnostic imaging in the diagnosis of Parkinson’s Disease and for manufacture in bulk for investigational new drug (IND) submission and clinical trials. Any other such applicant, and any person who is presently registered with DEA to manufacture such a substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, VA 22152; and must be filed no later than November 17, 2009. erowe on DSK5CLS3C1PROD with NOTICES By Notice dated June 15, 2009, and published in the Federal Register on June 23, 2009 (74 FR 29718), Aptuit, 10245 Hickman Mills Drive, Kansas City, Missouri 64137, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Marihuana (7360), a basic class of controlled substance listed in schedule I. The company plans to import a finished pharmaceutical product containing cannabis extracts in dosage form for packaging for a clinical trial study. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and § 952(a) and determined that the registration of Aptuit to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Aptuit to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and § 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. The company plans to import these controlled substances for the manufacture of reference standards. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and § 952(a) and determined that the registration of AllTech Associates, Inc. to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated AllTech Associates, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and § 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: September 11, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–22451 Filed 9–17–09; 8:45 am] Dated: September 11, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–22452 Filed 9–17–09; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P VerDate Nov<24>2008 15:10 Sep 17, 2009 Jkt 217001 Drug Schedule Gamma Hydroxybutyric Acid (2010). Heroin (9200) ............................... Cocaine (9041) ............................. Codeine (9050) ............................. Hydrocodone (9193) ..................... Meperidine (9230) ........................ Methadone (9250) ........................ Morphine (9300) ........................... PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 I I II II II II II II Dated: September 14, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–22503 Filed 9–17–09; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances Notice of Registration By Notice dated June 3, 2009, and published in the Federal Register on June 9, 2009, (74 FR 27350), Norac Inc., 405 S. Motor Avenue, P.O. Box 577, Azusa, California 91702–3232, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Nabilone (7379), a basic class of controlled substance listed in schedule II. The company plans to manufacture the bulk controlled substance for use in product development and for distribution to its customers. No comments or objections have been received. DEA has considered the E:\FR\FM\18SEN1.SGM 18SEN1 Federal Register / Vol. 74, No. 180 / Friday, September 18, 2009 / Notices factors in 21 U.S.C. 823(a) and determined that the registration of Norac Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Norac Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: September 11, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–22453 Filed 9–17–09; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Employee Benefits Security Administration All written comments and requests for a public hearing concerning the proposed exemption should be sent to the Office of Exemption Determinations, Employee Benefits Security Administration, Room N–5700, U.S. Department of Labor, 200 Constitution Avenue, NW., Washington DC 20210, Attention: Application No. L–11568. Interested persons are also invited to submit comments and/or hearing requests to EBSA via e-mail or FAX. Any such comments or requests should be sent either by e-mail to: gm@dol.gov, or by FAX to (202) 219– 0204 by the end of the scheduled comment period. The application for exemption and the comments received will be available for public inspection in the Public Documents Room of the Employee Benefits Security Administration, U.S. Department of Labor, Room N–1513, 200 Constitution Avenue, NW., Washington, DC 20210. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Karen E. Lloyd, Office of Exemption Determinations, Employee Benefits Security Administration, U.S. Department of Labor, telephone (202) 693–8547. (This is not a toll-free number.) [Application No. L–11568] Notice of Proposed Individual Exemption Involving General Motors Corporation, Located in Detroit, MI AGENCY: Employee Benefits Security Administration, U.S. Department of Labor. ACTION: Notice of proposed individual exemption. erowe on DSK5CLS3C1PROD with NOTICES Written comments and requests for a public hearing on the proposed exemption should be submitted to the Department within 45 days from the date of publication of this Federal Register Notice. This document contains a notice of proposed individual exemption from the restrictions of sections 406(a)(1)(A), 406(a)(1)(B), 406(a)(1)(D), 406(a)(1)(E), 406(a)(2), 406(b)(1), 406(b)(2), and 407(a) of ERISA. The proposed exemption has been requested in an application filed by General Motors Corporation pursuant to section 408(a) of ERISA and in accordance with the procedures set forth in 29 CFR 2570, Subpart B (55 FR 32836, August 10, 1990). Effective December 31, 1978, section 102 of Reorganization Plan No. 4 of 1978, (43 FR 47713, October 17, 1978) transferred the authority of the Secretary of the Treasury to issue exemptions of the type requested to the Secretary of Labor. Accordingly, this proposed exemption is being issued solely by the Department. SUPPLEMENTARY INFORMATION: This document contains a notice of pendency before the Department of Labor (the Department) of a proposed individual exemption from certain prohibited transaction restrictions of the Employee Retirement Income Security Act of 1974 (the Act or ERISA). The transactions involve the UAW General Motors Company Retiree Medical Benefits Plan (the New GM VEBA Plan) and its associated UAW Retiree Medical Benefits Trust (the VEBA Trust) (collectively the VEBA).1 The proposed exemption, if granted, would affect the VEBA, its participants and beneficiaries. DATES: Effective Date: If granted, this proposed exemption will be effective as of July 10, 2009. 1 Because the New GM VEBA Plan will not be qualified under section 401 of the Internal Revenue Code of 1986, there is no jurisdiction under Title II of the Act pursuant to section 4975 of the Code. However, there is jurisdiction under Title I of the Act. VerDate Nov<24>2008 15:10 Sep 17, 2009 Jkt 217001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 47963 Summary of Facts and Representations 2 The Applicant Prior to its bankruptcy filing on June 1, 2009, General Motors Corporation (Old GM) and its subsidiaries were engaged primarily in the worldwide development, production, and marketing of cars, trucks, and related parts. Old GM had its largest operating presence in North America. As of March 31, 2009, Old GM had total assets on its consolidated balance sheet of $82,290,000,000 and liabilities of $172,810,000,000. By motion filed June 1, 2009, in In re General Motors Corporation, 3 Old GM sought approval for the sale of substantially all of its assets to a purchaser sponsored by the United States Department of the Treasury (U.S. Treasury). On July 10, 2009, following approval of the U.S. Bankruptcy Court for the Southern District of New York, certain assets and liabilities of Old GM were sold to General Motors Company (New GM).4 New GM maintains its headquarters in Detroit, MI, and employs 235,000 people throughout the world. Background Throughout much of 2005, Old GM and the International Union, United Automobile, Aerospace and Agricultural Implement Workers of America (UAW) engaged in extended discussions concerning the impact of rising health care costs on Old GM’s financial condition. During these discussions, Old GM asserted that it had the right to unilaterally modify the retiree health benefits under the General Motors Health Care Program for Hourly Employees (‘‘Old GM Plan’’) and that, if no agreement was reached to address the economic burden of its retiree health obligation, Old GM would do so unilaterally. The UAW disagreed with Old GM’s position and asserted that retiree benefits were vested and that Old GM did not have the right to modify them unilaterally. The UAW and a class of retirees (‘‘Class’’) sued Old GM over this issue, and after an extensive review by the UAW and class counsel (Class Counsel) of Old GM’s ability to continue providing retiree health care benefits, the parties entered into a settlement 2 The Summary of Facts and Representations is based on the Applicant’s representations and does not reflect the views of the Department. 3 No. 09–50026 (Bankr. S.D.N.Y.). 4 Following the asset sale, Old GM was renamed Motors Liquidation Company. For the operations, assets and liabilities that were not transferred to New GM, the chapter 11 bankruptcy proceeding will continue in order to resolve creditors’ claims and wind down those operations in an orderly way. E:\FR\FM\18SEN1.SGM 18SEN1

Agencies

[Federal Register Volume 74, Number 180 (Friday, September 18, 2009)]
[Notices]
[Pages 47962-47963]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-22453]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances Notice of Registration

    By Notice dated June 3, 2009, and published in the Federal Register 
on June 9, 2009, (74 FR 27350), Norac Inc., 405 S. Motor Avenue, P.O. 
Box 577, Azusa, California 91702-3232, made application by letter to 
the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of Nabilone (7379), a basic class of controlled substance 
listed in schedule II.
    The company plans to manufacture the bulk controlled substance for 
use in product development and for distribution to its customers.
    No comments or objections have been received. DEA has considered 
the

[[Page 47963]]

factors in 21 U.S.C. 823(a) and determined that the registration of 
Norac Inc. to manufacture the listed basic class of controlled 
substance is consistent with the public interest at this time. DEA has 
investigated Norac Inc. to ensure that the company's registration is 
consistent with the public interest. The investigation has included 
inspection and testing of the company's physical security systems, 
verification of the company's compliance with state and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above 
named company is granted registration as a bulk manufacturer of the 
basic class of controlled substance listed.

    Dated: September 11, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-22453 Filed 9-17-09; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.